← All Cadrenal Therapeutics, INC filings

Cadrenal Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CVKD
Cadrenal Therapeutics, INC
10-K: Cadrenal Therapeutics Faces Going Concern Warning Amidst Pipeline Progress
Cadrenal Therapeutics reports increased losses and a significant cash burn in its 2025 annual report, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate CAD-1005 towards a pivotal Phase 3 trial.
NASDAQ
CVKD
Cadrenal Therapeutics, INC
10-K: Cadrenal Therapeutics Reports 2024 Annual Results and Provides Business Update
Cadrenal Therapeutics' 2024 annual report highlights the company's focus on developing tecarfarin for rare cardiovascular conditions and its recent collaboration with Abbott.
NASDAQ
CVKD
Cadrenal Therapeutics, INC
10-K: Cadrenal Therapeutics Reports 2023 Annual Results, Focuses on Tecarfarin Development
Cadrenal Therapeutics' 2023 annual report highlights the company's focus on developing tecarfarin for rare cardiovascular conditions, while also detailing financial results and risks.